A multicenter study performed in the United States confirmed that: patients with ITP who previously used other TPO-RAs (eltrombopag or romiplostim) and responded poorly exhibited a high response rate to avatrombopag (71). This evidence concerns the gene TPO and autoimmune thrombocytopenic purpura.